Energy drinks and stimulant supplements draw a sharper cardiovascular warning signal
Reports of serious heart problems appeared far more often in FDA safety data tied to energy drinks and stimulant supplements than in reports involving products without caffeine or other stimulants. The most striking signal involved cardiac arrest, which was reported about 11 times more frequently in the stimulant-containing group, alongside a 4.5-fold higher reporting frequency for heart attacks. The analysis also found more reports of ventricular arrhythmias, palpitations, chest pain, rapid heart rate, and fainting.
The pattern does not prove causation. It does, however, place a familiar consumer product category under a more serious clinical lens.
The FDA database points to a concentrated safety signal
Researchers reviewed 28,345 reports of possible adverse events submitted to an FDA safety database between 2017 and 2025. Of those, 854 involved energy drinks or dietary supplements containing caffeine or other stimulants, while 27,491 involved comparison products without stimulant ingredients, including soft drinks, smoothies, vitamins, protein bars, and meal replacement shakes. The analysis grouped products by ingredient class rather than by brand, so the findings apply to broad categories of stimulant-containing products rather than to a single manufacturer.
The stimulant group included caffeine, methylxanthines such as theobromine, guarana, yerba mate, and green tea or coffee extracts, along with sympathomimetics such as synephrine, yohimbine, ephedra, DMAA, and higenamine. Those ingredients are not interchangeable in potency, but they share a pharmacologic theme: they can raise sympathetic tone, increase heart rate, and push the cardiovascular system toward a more activated state. In vulnerable people, or in someone who stacks products across the day, that physiological stress can become clinically relevant.
One sentence captures the concern plainly: reports of cardiac arrest clustered at a far higher rate around stimulant products than around non-stimulant foods and supplements.
Young adults made up a large share of the reports
Adults ages 18 to 34 accounted for about 45% of the cardiovascular event reports involving caffeine and stimulant products. Comparable patterns appeared in reports submitted for men and women. The age distribution stands out because it runs against the common assumption that serious heart events are mainly a disease of older adults with established coronary risk factors.
Several explanations could account for the pattern. Younger adults may consume these products more often, may use them before intense exercise, or may combine them with alcohol or other drugs. Some may have an undiagnosed arrhythmia substrate, congenital abnormality, or inherited susceptibility that never comes to attention until a stimulant exposure tips the balance. None of those possibilities can be confirmed from spontaneous reports alone, but each is biologically plausible.
The bedside implication is immediate: when a younger patient arrives with palpitations, chest pain, or fainting, the exposure history should include energy drinks and stimulant supplements, not just prescription medications and illicit drugs.
Why caffeine dose and product strength matter
The cardiovascular concern is not just the presence of caffeine. It is also the concentration, the dose consumed, and the way these products are marketed and used. A 2026 American Heart Association scientific statement indicates that most adults can generally consume up to 400 mg of caffeine daily without significant safety concerns, roughly the equivalent of up to five 8-ounce cups of regular black coffee. Yet energy drinks can deliver up to three times as much caffeine per fluid ounce as brewed coffee, and some pre-workout supplements contain more than 12 times the concentration found in coffee.
Those numbers matter because many consumers do not track milligrams. They track cans, scoops, or servings. A person may believe a product is harmless because it sits beside soda or bottled water in a store, while in practice the total stimulant load may be high enough to produce tachycardia, blood pressure elevation, or rhythm instability. Layer in exercise, dehydration, sleep deprivation, or co-use with other stimulants, and the physiologic burden can rise further.
The reporting ratios should not be mistaken for absolute risk
The comparison in this analysis reflects reporting frequency within a safety database, not the true incidence of events in the population. That distinction is crucial. The database is based on voluntary reports from consumers, clinicians, manufacturers, and others, so it does not capture every adverse event and does not provide the number of exposed consumers who had no complications. It also cannot determine how many people experienced a heart problem without submitting a report.
Because of those limits, the findings cannot be translated into a statement that energy drink consumers face an 11-fold higher actual risk of cardiac arrest. They do, however, identify a strong signal worth monitoring more closely. In pharmacovigilance terms, a signal is not proof, but it is not noise either.
Gregory M. Marcus, who did not participate in the research, framed the issue in clinical terms: biologic reasons exist for caffeine-related cardiovascular harm, but the data do not prove that the products caused the reported events. That caution is appropriate, especially when voluntary reporting data are being used to infer safety trends.
Regulatory gaps leave consumers with less protection than prescription drugs
Energy drinks and stimulant supplements are regulated as foods or dietary supplements rather than medications. As a result, they are not subjected to the same premarket safety testing required for drugs. That regulatory structure helps explain why cardiovascular events can accumulate in real-world use before a clear risk profile is established.
The market context matters too. Sales of energy drinks have more than doubled over the past decade and exceeded $20 billion in 2024. Wide use does not automatically mean wide harm, but it does mean a safety signal can reach a large exposed population before clinicians or regulators fully appreciate the scope of the problem.
For everyday practice, the message is to treat stimulant exposure as part of the differential when evaluating unexplained palpitations, syncope, chest discomfort, or resuscitated arrest in younger patients. A routine medication list can miss the relevant exposure entirely if nobody asks about energy drinks, pre-workout powders, or “natural” stimulant blends.
What remains unresolved in the safety data
The database cannot show whether the products themselves were responsible for the heart events, whether another condition was present, or whether a behavior around product use drove the signal. It also cannot compare brand-specific formulations, assess dose-response relationships, or identify which ingredient combinations are most dangerous. The finding that nearly half of the reports involved adults under 35 raises a practical concern, but the mechanism remains uncertain.
That uncertainty is exactly why systematic surveillance matters. A better understanding of stimulant load, co-exposures, and patient susceptibility could separate occasional low-risk use from patterns that precede arrhythmia, ischemia, or collapse. Until then, the safest clinical stance is simple: ask about these products early, and do not dismiss them as benign just because they are sold like ordinary beverages.